We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Mylan, Pfizer Barely Put Dent In EpiPen Antitrust MDL

Law360 (August 20, 2018, 9:53 PM EDT) -- Mylan NV and Pfizer Inc. on Monday largely failed to scale down multidistrict litigation over sky-high prices for emergency allergy treatment EpiPen, as a Kansas federal judge mostly refused to throw out wide-ranging consumer claims of...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.